| Dokument | Liczba publikacji |
|---|---|
| CLINICAL TRIAL | 346 |
| JOURNAL ARTICLE | 316 |
| CLINICAL TRIAL, PHASE II | 47 |
| CLINICAL TRIAL, PHASE I | 38 |
| CLINICAL TRIAL PROTOCOL | 37 |
| COMPARATIVE STUDY | 28 |
| CLINICAL TRIAL, PHASE III | 22 |
| LETTER | 18 |
| CONTROLLED CLINICAL TRIAL | 8 |
| CASE REPORTS | 5 |
| ADAPTIVE CLINICAL TRIAL | 4 |
| EQUIVALENCE TRIAL | 3 |
| CLINICAL TRIAL, PHASE IV | 1 |
| Author Keywords (DE) | Articles | Keywords-Plus (ID) | Articles |
|---|---|---|---|
| COVID-19 | 48 | HUMANS | 113 |
| IVERMECTIN | 38 | COVID-19 | 108 |
| SARS-COV-2 | 30 | SARS-COV-2 | 84 |
| CHLOROQUINE | 10 | IVERMECTIN | 73 |
| CORONAVIRUS | 9 | ANTIVIRAL AGENTS | 58 |
| ANTIVIRAL | 8 | PANDEMICS | 35 |
| HYDROXYCHLOROQUINE | 8 | PNEUMONIA VIRAL | 28 |
| REMDESIVIR | 7 | CORONAVIRUS INFECTIONS | 26 |
| AZITHROMYCIN | 4 | MALE | 24 |
| DOXYCYCLINE | 4 | ANIMALS | 23 |
| TREATMENT | 4 | BETACORONAVIRUS | 23 |
| DENGUE VIRUS | 3 | FEMALE | 23 |
| DEXAMETHASONE | 3 | DRUG REPOSITIONING | 22 |
| FAVIPIRAVIR | 3 | ANTIPARASITIC AGENTS | 20 |
| PROTOCOL | 3 | HYDROXYCHLOROQUINE | 20 |
| Nazwa chemiczna | Liczba publikacji |
|---|---|
| oxygen | 107 |
| hydroxychloroquine | 56 |
| tocilizumab | 22 |
| azithromycin | 18 |
| lopinavir/ritonavir | 18 |
| favipiravir | 15 |
| creatinine | 14 |
| chloroquine | 13 |
| remdesivir | 13 |
| water | 13 |
| dexamethasone | 12 |
| glucose | 12 |
| hcq | 12 |
| methylprednisolone | 11 |
| alcohol | 10 |
| Nazwa genu | Liczba publikacji |
|---|---|
| c-reactive protein | 51 |
| il-6 | 45 |
| spike | 29 |
| cd4 | 27 |
| crp | 25 |
| cd8 | 21 |
| interleukin-6 | 19 |
| tnf-alpha | 14 |
| il-8 | 13 |
| il-10 | 12 |
| ifn-gamma | 9 |
| ace2 | 7 |
| il-1beta | 7 |
| interleukin-6 receptor | 7 |
| insulin | 6 |